Nancy Rector
Pulmonary Disease · Little Rock, ARNPI 1538195086
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.0% of the total across 242 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by GSK at 24.1% of the total.
Across 242 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Boehringer Ingelheim$681
- AstraZeneca$637
- Regeneron Healthcare Solutions, Inc.$258
- Mallinckrodt Hospital Products Inc.$214
- Mylan Specialty L.p.$199
- plus $1K from 22 others
What the payments were for
- Food & beverage$4,07795%
- Education$2135%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 89 | $1,033 |
| Boehringer Ingelheim | 40 | $681 |
| AstraZeneca | 30 | $637 |
| Regeneron Healthcare Solutions, Inc. | 6 | $258 |
| Mallinckrodt Hospital Products Inc. | 8 | $214 |
| Mylan Specialty L.p. | 9 | $199 |
| Actelion Pharmaceuticals US, Inc. | 7 | $182 |
| Grifols USA, LLC | 9 | $180 |
| Sanofi | 8 | $163 |
| Sunovion Pharmaceuticals Inc. | 7 | $122 |
| Advanced Respiratory, Inc | 5 | $109 |
| Fisher & Paykel Healthcare Inc | 1 | $88 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $80 |
| Mallinckrodt Enterprises LLC | 3 | $54 |
| Merck | 2 | $39 |
| Amgen | 2 | $39 |
| Hologic Sales And Service, LLC | 1 | $30 |
| AbbVie | 1 | $22 |
| Johnson & Johnson | 1 | $21 |
| Nabriva Therapeutics, PLC | 1 | $19 |
| Baxter Healthcare | 1 | $19 |
| Pfizer | 1 | $18 |
| Shire North American Group Inc | 1 | $16 |
| CSL Behring | 1 | $15 |
| Inogen, Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Circassia Inc. | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEZSPIRE$106
How this compares
$4,290 in reported general payments places this provider in the 55th percentile of 102 pulmonary disease providers in Arkansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 81 | $60,137 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 18 | $11,664 |
| Spiriva HandihalerTiotropium Bromide | 12 | $10,129 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 15 | $7,065 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $6,773 |
| Incruse ElliptaUmeclidinium Bromide | 17 | $5,428 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $2,359 |
| Ventolin HfaAlbuterol Sulfate | 37 | $2,200 |
| Roflumilast | 12 | $1,609 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 57 | $1,569 |
| Azithromycin | 26 | $198 |
| Montelukast Sodium | 18 | $132 |
| Prednisone | 12 | $53 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $1,033 | $84,001131 claims |
| AstraZenecaBevespi Aerosphere | $637 | $7,06515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 102 pulmonary disease providers in Arkansas.
Other pulmonary disease in Little Rock
- Nikhil MeenaLittle Rock$63K
- Hanan Khadam-MakhoulLittle Rock$15K
- Raghu ReddyLittle Rock$13K
- Eyad AbochaleLittle Rock$11K
- Krishna Siva Sai KakkeraLittle Rock$11K
- Samer HomsiLittle Rock$9K
- Nathan HillLittle Rock$9K
- Jose CaceresLittle Rock$6K
- Moeezullah BegLittle Rock$5K
- Rosa ArancibiaLittle Rock$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.